Comparison of different prognostic scores versus physician’s subjective prognosis in patients with advanced/metastatic renal cell carcinoma treated with temsirolimus in regular clinical setting: An analysis of the STAR-TOR registry.

441Background: In treatment of metastatic renal cell carcinoma (mRCC) patients several prognostic scores are used: the MSKCC-, IMDC-, and for pts treated with Temsirolimus (TEMS) the Hudes-score. We assessed prognostic value of these scores in TEMS treated cohort and compared the results with physician’s prognosis. Methods: A German multicenter registry for pts with mRCC (NCT00700258) was established to evaluate the safety and efficacy of TEMS in clinical routine. We retrospectively analyzed the data to compare established prognostic scores with risk assessment by the treating physician and match them with survival outcomes. Results: From 02/2008-05/2015, 547 mRCC pts were treated with TEMS. Risk was calculated for 305 (MSKCC), 248 (IMDC), and 187 (Hudes) pts. Physician’s prognosis was documented for 530 pts. Multivariate survival analyses are shown in table below. Abbreviations: g (good), i (intermediate), p (poor), n-p (non-poor). Conclusions: Risk assessment by treating physician is as meaningful as ob...